Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Novavax reported $34.09M in Cost of Sales for its fiscal quarter ending in March of 2023.

Cost Of Sales Change
Adma Biologics ADMA:US USD 40.5M 4.7M
Agenus AGEN:US USD 2.29M 5.4M
AstraZeneca AZN:LN USD 2.05B 458M
BioCryst Pharmaceuticals BCRX:US USD 938K 1.56M
Dynavax Technologies DVAX:US USD 14.71M 62.78M
GlaxoSmithKline GSK:LN GBP 1.9B 274M
MannKind MNKD:US USD 16.21M 89K
Merck & Co MRK:US USD 3.35B 491M
Moderna Inc MRNA:US USD 792M 1.13B
Novartis NVS:US USD 3.83B 8M
Novavax NVAX:US USD 34.09M 147.68M
Peregrine Pharmaceuticals PPHM:US USD 28.19M 2.42M
Pfizer PFE:US USD 5.03B 4.8B
Sarepta Therapeutics SRPT:US USD 35.02M 4.22M
TG Therapeutics TGTX:US USD 857K 854K